Adverse Drug Reaction Classification System

         

Pharmaceutical Information
Drug Name Nelfinavir mesylate
Drug ID BADD_D01550
Description Nelfinavir is a potent HIV-1 protease inhibitor. It is used in combination with other antiviral drugs in the treatment of HIV in both adults and children. Nelfinavir inhibits the HIV viral proteinase enzyme which prevents cleavage of the gag-pol polyprotein, resulting in noninfectious, immature viral particles.
Indications and Usage Used in combination with other antiviral drugs in the treatment of HIV in both adults and children.
Marketing Status approved
ATC Code J05AE04
DrugBank ID DB00220
KEGG ID D00899
MeSH ID D019888
PubChem ID 64142
TTD Drug ID Not Available
NDC Product Code 63010-010; 63010-027
UNII 98D603VP8V
Synonyms Nelfinavir | Viracept | AG 1343 | AG1343 | AG-1343 | Nelfinavir Mesylate | Mesylate, Nelfinavir | Nelfinavir Monomethane Sulfonate | Monomethane Sulfonate, Nelfinavir | Sulfonate, Nelfinavir Monomethane
Chemical Information
Molecular Formula C33H49N3O7S2
CAS Registry Number 159989-65-8
SMILES CC1=C(C=CC=C1O)C(=O)NC(CSC2=CC=CC=C2)C(CN3CC4CCCCC4CC3C(=O)NC(C)(C)C)O.CS(=O)(=O )O
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice.
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Pneumonia11.01.09.003; 22.07.01.003---
Pruritus23.03.12.001--
Pyrexia08.05.02.003--
Rash23.03.13.001---
Rash maculo-papular23.03.13.004--
Rhabdomyolysis15.05.05.002--
Rhinitis11.01.13.004; 22.07.03.006--
Seizure17.12.03.001--
Sexual dysfunction19.08.05.002; 21.03.02.003---
Sinusitis11.01.13.005; 22.07.03.007--
Skin disorder23.03.03.007---
Sleep disorder19.02.04.001---
Somnolence17.02.04.006; 19.02.05.003--
Stomatitis07.05.06.005--
Suicidal ideation19.12.01.003--
Thrombocytopenia01.08.01.002---
Torsade de pointes02.03.04.005---
Urine abnormality20.02.01.013---
Urticaria10.01.06.001; 23.04.02.001--
Vomiting07.01.07.003--
Fat redistribution14.08.04.002---
Lipodystrophy acquired14.08.04.008; 23.07.01.003---
Musculoskeletal discomfort15.03.04.001---
Affect lability19.04.01.001---
Body fat disorder14.08.04.012---
Haemorrhage24.07.01.002---
Angiopathy24.03.02.007---
Blood alkaline phosphatase increased13.04.02.004--
Hepatic enzyme increased13.03.04.028---
Connective tissue disorder10.04.04.026; 15.06.01.006---
The 4th Page    First    Pre   4 5    Next   Last    Total 5 Pages